Heartflow, Inc. (NASDAQ:HTFL) Receives $36.60 Consensus PT from Analysts

Heartflow, Inc. (NASDAQ:HTFL) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $36.60.

Several equities analysts have issued reports on HTFL shares. Morgan Stanley started coverage on shares of Heartflow in a report on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 price objective on the stock. Canaccord Genuity Group increased their price objective on shares of Heartflow from $35.00 to $39.00 and gave the company a “buy” rating in a report on Monday, September 22nd. Stifel Nicolaus started coverage on shares of Heartflow in a report on Tuesday, September 2nd. They set a “buy” rating and a $35.00 price objective on the stock. Zacks Research raised shares of Heartflow to a “hold” rating in a report on Wednesday, September 3rd. Finally, Wall Street Zen raised shares of Heartflow to a “hold” rating in a report on Saturday, August 16th.

Heartflow Trading Down 0.1%

Shares of NASDAQ HTFL opened at $38.30 on Wednesday. The business’s fifty day moving average price is $33.85. Heartflow has a 1 year low of $26.56 and a 1 year high of $41.22.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Friday, September 19th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The business had revenue of $43.42 million for the quarter, compared to analyst estimates of $43.20 million.

Institutional Investors Weigh In On Heartflow

A hedge fund recently bought a new stake in Heartflow stock. TFC Financial Management Inc. bought a new stake in Heartflow, Inc. (NASDAQ:HTFL) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,200 shares of the company’s stock, valued at approximately $40,000.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.